Anuh Pharma Limited — PPTs, 17-11-2025: Investor Presentation

Anuh Pharma saw H1 FY26 revenue jump 22.54% YoY to 372.36 Cr. However, PAT declined 35.18% to 15.91 Cr, with EPS at 1.59. This dip was due to lower sales of high-margin products, non-recurring maintenance, and adverse currency movements.

The company is driving growth through market expansion, a focused push in matured markets via a dedicated CMO, and R&D into diabetic care, anticoagulants, and next-generation anti-malarials. Recent developments include adding a new intermediate block, boosting total reactor capacity to 240 KL, increasing effluent treatment capacity, and commissioning new solar power. Overall manufacturing capacity expanded to 2400 MTPA.

Management is optimistic for H2 FY26, forecasting a strong margin recovery from better operational efficiencies, high-margin product rebound, and stabilizing costs. They aim for a steady 15-16% annual growth, focusing on innovative complex chemistry and lifestyle drugs. #AnuhPharma #APIs